You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Let’s Talk: Community Perspectives on Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndrome

  • Authors: Naval G. Daver, MD; David A. Sallman, MD; Rory M. Shallis, MD; Eunice S. Wang, MD
  • CME / ABIM MOC / CE Released: 12/29/2022
  • Valid for credit through: 12/29/2023
Start Activity

  • Credits Available

    Physicians - maximum of 1.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.50 ABIM MOC points

    Nurses - 1.50 ANCC Contact Hour(s) (1.5 contact hours are in the area of pharmacology)

    Pharmacists - 1.50 Knowledge-based ACPE (0.150 CEUs)

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematologist/oncologists, pathologists, oncology nurses/nurse practitioners, physician assistants, and oncology pharmacists.

The goal of this activity is for hematology/oncology specialists practicing in a community setting to be better able to optimize their treatment of patients with AML and HR-MDS.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical trial data for treatment options for AML and HR-MDS
  • Have greater competence related to
    • Personalizing treatment strategies for patients with AML and HR-MDS
    • Mitigating toxicities of therapies used to treat AML and HR-MDS
  • Demonstrate greater confidence in their ability to
    • Discuss new therapeutic advances for treating AML and HR-MDS


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Moderator

  • Naval Daver, MD

    Associate Professor
    Department of Leukemia
    Director
    Leukemia Research Alliance Program
    The University of Texas
    MD Anderson Cancer Center
    Houston, Texas

     

    Disclosures

    Naval G. Daver, MD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie Inc; Agios Pharmaceuticals; Amgen, Inc.; AROG Pharmaceuticals, INC.; Astellas Pharma, Inc.; Bristol Myers Squibb Company; Celgene Corporation; Daichii Sankyo, Inc.; Genentech; Gilead Sciences, Inc.; ImmunoGen, Inc.; Jazz Pharmaceuticals, Inc.; Novartis; Pfizer, Inc.; SERVIER; Shattuck Labs, Inc; Syndax Pharmaceuticals, Inc.; Trillium
    Research funding from: AbbVie Inc.; Amgen, Inc.; Astellas Pharma, Inc.; Bristol Myers Squibb Company; Daiichi Sankyo, Inc.; FATE Therapeutics, Inc.; Genentech; Gilead Sciences, Inc.; GlycoMimetics, Inc.; Hanmi Pharm. Co., Ltd.; ImmunoGen, Inc.; NovImmune SA; Pfizer, Inc.; SERVIER; Trillium; Trovagene

Panelists

  • David A. Sallman, MD

    Assistant Member and Myeloid Section Head
    Malignant Hematology Department
    H. Lee Moffitt Cancer Center and Research Institute
    Assistant Professor
    Department of Oncologic Sciences
    University of South Florida
    Tampa, Florida

     

    Disclosures

    David A. Sallman, MD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie Inc.; Affimed Gmbh; AvenCell; bluebird bio, Inc.; Bristol Myers Squibb Company; Gilead Sciences, Inc.; Intellia; Intellisphere, LLC; Jasper Therapeutics; Kite Pharma, Inc.; Molecular Partners A.G.; Novartis; Precigen, Inc.; Shattuck Labs, Inc; SERVIER; Syndax Pharmaceuticals, Inc.; Takeda; Zentalis
    Speaker or member of speakers bureau for: Bristol Myers Squibb Company; Incyte; SERVIER
    Research funding from: Aprea Therapeutics; Jazz Pharmaceuticals, Inc.

  • Rory M. Shallis, MD

    Assistant Professor
    Section of Hematology
    Department of Internal Medicine
    Yale School of Medicine
    Yale Cancer Center
    New Haven, Connecticut

     

    Disclosures

    Rory M. Shallis, MD, has the following relevant financial relationships:
    Consultant or advisor for: Bristol Myers Squibb Company; Gilead Sciences, Inc.

  • Eunice S. Wang, MD

    Professor of Oncology
    Chief
    Leukemia Service
    Director
    Roswell Park Comprehensive Cancer Institute
    Buffalo, New York

     

    Disclosures

    Eunice S. Wang, MD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie Inc.; Amgen, Inc.; Astellas Pharma, Inc.; Bristol Myers Squibb Company; Daiichi Sankyo, Inc.; Genentech; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Kite Pharma, Inc.; Mana Therapeutics; Novartis; NuProbe; PharmaEssentia; Pfizer, Inc.; Stemline; Takeda
    Speaker or member of speakers bureau for: Astellas; Dava Oncology; Pfizer, Inc.; Stemline
    Research funding from: Amgen, Inc.; Aptevo; AROG Pharmaceuticals, INC.; Cellectis; Gilead Sciences, Inc.; ImmunoGen, Inc.; Incyte Corporation; Loxo Oncology; Pfizer, Inc.; Stemline

Editors

  • Heather P. Friedman, MPH

    Medical Education Director, Medscape, LLC

     

    Disclosures

    Heather P. Friedman, MPH, has no relevant financial relationships.

  • Kalanethee Paul-Pletzer, PhD

    Medical Education Director, Medscape, LLC

     

    Disclosures

    Kalanethee Paul-Pletzer, PhD, has no relevant financial relationships

Compliance Reviewer/Nurse Planner

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

     

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 1.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.50 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 1.50 contact hour(s) (0.150 CEUs) (Universal Activity Number: JA0007105-0000-22-426-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Let’s Talk: Community Perspectives on Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndrome

Authors: Naval G. Daver, MD; David A. Sallman, MD; Rory M. Shallis, MD; Eunice S. Wang, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 12/29/2022

Valid for credit through: 12/29/2023

processing....

Educational Impact Challenge

The goal of this activity is for hematology/oncology specialists practicing in a community setting to be better able to optimize their treatment of patients with AML and HR-MDS.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print